Header graphic for print
The Healthcare Investor Insights on Issues & Trends that Impact Investments in Healthcare & Life Science Businesses

Healthcare & Life Sciences Private Equity Deal Tracker: Warburg Pincus to Invest up to $300 Million in Vertice Pharma

Posted in Healthcare Services Investing

PE firm Warburg Pincus has announced it will invest up to $300 million in new pharmaceutical company Vertice Pharma.

Vertice Pharma, which has its U.S. headquarters in New Jersey, will focus on acquiring specialty pharmaceutical companies and products. It was launched by pharmaceutical industry veterans Don DeGolyer and Andrew Saik in partnership with Warburg Pincus.

Vertice Parma’s first acquisition is VistaPharm, a Birmingham, Ala.-based specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics.

Warburg Pincus, headquartered in New York, was founded in 1966. The firm focuses primarily on investing in healthcare and consumer products; technology, media and telecommunications; financial services; energy; and industrial and business services. It has invested more than $50 billion in more than 720 companies located in more than 35 countries.

We use cookies to enhance your experience of our website. By continuing to use this website, you agree to the use of these cookies. For more information and to learn how you can change your cookie settings, please see our policy.